In the past decade, the advent of targeted agents has become a survival benefit for patients with advanced cancers, and they have improved the cure rate in those treated in the adjuvant setting.
Oncology nurses are at the forefront to assist with education, recognition, and management of side effects and supportive care during treatment.
Presented by Ann Calkin, RN, OCN, the webinar will include:
The definition and examples of targeted therapies
Common (and some uncommon) side effects
Useful management techniques
A question-and-answer period following the presentation
As we continue to see advancement within cancer research, tailored patient treatment seems to be the future of oncology care.
More Blogs from...
Community editor Michelle Bragazzi talks about pay inequality among male and female nurses.
Community editor Michelle Bragazzi wants to know what advice you would provide to a new oncology nurse.
Community editor Michelle Bragazzi explains the effectiveness of Kyprolis in patients with multiple myeloma.
Community editor Michelle Bragazzi would like you to take a survey on occupational exposure in the workplace.
Community editor Michelle Bragazzi discusses the impact net worth has on breast cancer treatment compliance.
Tuesday, October 29, 2013 12:00 PM EDT
Ellen T. Matloff, MS, CGC , this webinar will highlight:
How to determine which patients require genetic counseling
How to help prepare your patients for the genetic counseling process
Testing options that are now available
How you can utilize this data in managing your patients and their family members
Participants will also be able to ask questions during a live question and answer period with speaker
Ellen T. Matloff, MS, CGC .
Wednesday, August 28, 2013 12:00 PM EDT
Wednesday, June 26, 2013 12:00 PM EDT
Wednesday, April 10, 2013 12:00 PM EDT
Have a question or topic but don't want to write a blog? Post it on our readerboards and get
feedback from the community!
on neesur timing of Cisplatin and radiation
on LizzN Oncology Nurse Navigator
FDA Approves New Multiple Myeloma Drug Melissa Scott, BSN, RN, OCN, 2/27/2015
The US Food and Drug Administration (FDA) recently expedited approval for another cancer drug. On February 23, 2015, the FDA approved panobinostat (Farydak), a third-line treatment ...